Does the Number of Previous Vaginal Deliveries Affect Overactive Bladder Symptoms and their Response to Treatment?

被引：14

作者：

Witte, Lambertus P. W. ^{[1
]}

Peschers, Ursula ^{[2
]}

Vogel, Monika ^{[3
]}

de la Rosette, Jean J. M. C. H. ^{[1
]}

Michel, Martin C. ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Pharmacol & Pharmacotherapy & Urol, NL-1105 AZ Amsterdam, Netherlands

[2] Pelv Floor Ctr, Munich, Germany

[3] Astellas Pharma GmbH, Munich, Germany

来源：

LUTS-LOWER URINARY TRACT SYMPTOMS | 2009年 / 1卷 / 02期

关键词：

muscarinic antagonist; overactive bladder; solifenacin; vaginal delivery; EXTENDED-RELEASE; URINARY-INCONTINENCE; RISK-FACTORS; EFFICACY; TOLERABILITY; TOLTERODINE; SOLIFENACIN; PREVALENCE; QUESTIONNAIRE; PERCEPTION;

D O I：

10.1111/j.1757-5672.2009.00051.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: To explore associations between the number of vaginal deliveries (primary aim) or gender (secondary aim) and overactive bladder (OAB) symptoms as well as their response to treatment with a muscarinic antagonist. Methods: Preplanned secondary analysis of an observational study of solifenacin in OAB patients. Episode frequencies of OAB symptoms, pad use and scores on OAB rating scales were documented in 4450 patients before and after a 12-14 week treatment period with solifenacin 5 or 10 mg. Results: Women without, and with one, two or more than two vaginal deliveries and men were similar in their baseline characteristics. All groups also exhibited rather similar reductions in symptoms and improvements in rating scales upon treatment. Conclusion: These data indicate that solifenacin, and perhaps other muscarinic receptor antagonists, are similarly suitable for the treatment of OAB symptoms in both genders, irrespective of previous vaginal deliveries.

引用

页码：82 / 87

页数：6

共 30 条

[1]

Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052

[2] Validation of the Urgency Perception Scale [J].

Cardozo, L ;

Coyne, KS ;

Versi, E .

BJU INTERNATIONAL, 2005, 95 (04) :591-596

[3] The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis [J].

Chapple, Christopher R. ;

Khullar, Vik ;

Gabriel, Zahava ;

Muston, Dominic ;

Bitoun, Caty Ebel ;

Weinstein, David .

EUROPEAN UROLOGY, 2008, 54 (03) :543-562

[4] Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder [J].

Chapple, Christopher R. .

EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (17) :2421-2434

[5] A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial [J].

Chapple, CR ;

Martinez-Garcia, R ;

Selvaggi, L ;

Toozs-Hobson, P ;

Warnack, W ;

Drogendijk, T ;

Wright, DM ;

Bolodeoku, J .

EUROPEAN UROLOGY, 2005, 48 (03) :464-470

[6]

COCKETT AT, 1993, EMPFEHLUNGEN INT CON, P649

[7] Do overactive bladder symptoms improve after repair of anterior vaginal wall prolapse? [J].

Digesu, G. Alessandro ;

Salvatore, Stefano ;

Chaliha, Charlotte ;

Athanasiou, Stavros ;

Milani, Rodolfo ;

Khullar, Vik .

INTERNATIONAL UROGYNECOLOGY JOURNAL, 2007, 18 (12) :1439-1443

[8]

Dmochowski R., 2003, Neurourology and Urodynamics, V22, P411

[9] Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder [J].

Dmochowski, Roger ;

Abrams, Paul ;

Marschall-Kehrel, Daniela ;

Wang, Joseph T. ;

Guan, Zhonghong .

EUROPEAN UROLOGY, 2007, 51 (04) :1054-1064

[10] Establishing the prevalence of incontinence study: Racial differences in women's patterns of urinary incontinence [J].

Fenner, Dee E. ;

Trowbridge, Elisa R. ;

Patel, Divya L. ;

Fultz, Nancy H. ;

Miller, Janis M. ;

Howard, Denise ;

DeLancey, John O. L. .

JOURNAL OF UROLOGY, 2008, 179 (04) :1455-1460

← 1 2 3 →